# Dolutegravir Expanded Access Study

> **NCT01536873** · NA · COMPLETED · sponsor: **ViiV Healthcare** · enrollment: 200 (estimated)

## Conditions studied

- Infection, Human Immunodeficiency Virus
- HIV Infections

## Interventions

- **DRUG:** Dolutegravir

## Key facts

- **NCT ID:** NCT01536873
- **Lead sponsor:** ViiV Healthcare
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-06-14
- **Primary completion:** 2016-09-23
- **Final completion:** 2016-09-23
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2020-09-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01536873

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01536873, "Dolutegravir Expanded Access Study". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT01536873. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*